Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Dow
UBS
Express Scripts
Novartis
Moodys
Boehringer Ingelheim
Citi
Queensland Health
Chinese Patent Office

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020393

« Back to Dashboard

NDA 020393 describes ATROVENT, which is a drug marketed by Boehringer Ingelheim and is included in five NDAs. It is available from three suppliers. There are three patents protecting this drug. Additional details are available on the ATROVENT profile page.

The generic ingredient in ATROVENT is ipratropium bromide. There are eight drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.
Summary for 020393
Tradename:ATROVENT
Applicant:Boehringer Ingelheim
Ingredient:ipratropium bromide
Patents:0
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 020393
Mechanism of ActionCholinergic Antagonists
Medical Subject Heading (MeSH) Categories for 020393
Suppliers and Packaging for NDA: 020393
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATROVENT ipratropium bromide SPRAY, METERED;NASAL 020393 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0081 0597-0081-30 1 BOTTLE, PUMP in 1 CARTON (0597-0081-30) > 345 SPRAY, METERED in 1 BOTTLE, PUMP
ATROVENT ipratropium bromide SPRAY, METERED;NASAL 020393 NDA Physicians Total Care, Inc. 54868-5565 54868-5565-0 1 BOTTLE, PLASTIC in 1 CARTON (54868-5565-0) > 345 SPRAY, METERED in 1 BOTTLE, PLASTIC

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrength0.021MG/SPRAY
Approval Date:Oct 20, 1995TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Novartis
Mallinckrodt
Argus Health
Federal Trade Commission
Cipla
Fish and Richardson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot